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The safety and efficacy of gene therapy for inherited 
retinal  diseases  is  being  tested  in  humans  affected 
with Leber’s congenital amaurosis (LCA), an autosomal 
recessive blinding disease. Three independent studies 
have provided evidence that the subretinal administra-
tion of adeno-associated viral (AAV) vectors encoding 
RPE65 in patients affected with LCA2 due to mutations 
in the RPE65 gene, is safe and, in some cases, results in 
efficacy. We evaluated the long-term safety and efficacy 
(global effects on retinal/visual function) resulting from 
subretinal administration of AAV2-hRPE65v2. Both the 
safety and the efficacy noted at early timepoints persist 
through at least 1.5 years after injection in the three 
LCA2 patients enrolled in the low dose cohort of our 
trial. A transient rise in neutralizing antibodies to AAV 
capsid was observed but there was no humoral response 
to RPE65 protein. The persistence of functional amelio-
ration suggests that AAV-mediated gene transfer to the 
human retina does not elicit immunological responses 
which  cause  significant  loss  of  transduced  cells.  The 
persistence of physiologic effect supports the possibil-
ity that gene therapy may influence LCA2 disease pro-
gression. The safety of the intervention and the stability 
of  the  improvement  in  visual  and  retinal  function  in 
these subjects support the use of AAV-mediated gene 
augmentation therapy for treatment of inherited retinal 
diseases.
Received 17 August 2009; accepted 19 October 2009; published online 
1 December 2009. doi:10.1038/mt.2009.277
IntroductIon
Leber’s congenital amaurosis (LCA) is a group of hereditary   retinal 
dystrophies characterized by severe loss of retinal and visual func-
tions early in life with progressive degeneration of the cellular 
structure  of  the  retina.1,2  The  clinical  and  ophthalmic  features 
include severely reduced electroretinograms and pupillary light 
reflexes (PLRs), nystagmus (rhythmic, involuntary eye fixation 
instability), and fundus abnormalities on ophthalmoscopy.3,4
LCA is usually inherited as an autosomal recessive trait, and 
mutations in 15 different genes have been reported so far.5,6 LCA2, 
accounting for 10% of LCA,1,4 is caused by mutations in the RPE65 
gene. The biochemical blockade of the visual cycle resulting from the 
all-trans retinyl esters isomerase RPE65 deficiency causes a profound 
impairment in visual function with delayed histological degenera-
tion of retinal cells.7 Clinical assessment of LCA2 patients reveals, 
in most cases, the presence of retained visual capabilities in the first 
decade of life associated with nearly normal macular thickness.4
RPE65  gene replacement has been considered as a potential 
therapeutic strategy for LCA2, and successful proof-of-principle 
studies  in  LCA2  animal  models  using  a  replication-defective 
  adeno-associated viral vector (AAV)8–10 provided a strong basis for 
three independent phase 1 dose escalation studies of gene therapy 
in patients with LCA2.11–14 Preliminary results from the lowest 
dose cohort in our trial (three subjects) and from subjects treated 
in the low dose cohorts of two other trials (six subjects) show no 
evidence of serious adverse events, systemic dissemination of vec-
tor or harmful immunological responses to vector or transgene. 
We observed a macular hole following subretinal administration 
of vector in one subject,14 and a foveal thinning has been reported 
in a subject enrolled in a different trial.13
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Bainbridge et al.11 reported no improvements in visual   acuity, 
peripheral visual fields, or electroretinographic responses in the 
three subjects treated. One subject showed significantly increased 
visual function as judged by microperimetry and dark adapted 
perimetry  at  6  months  after  injection.  Hauswirth  et  al.  and 
Cideciyan et al. reported significantly higher dark adapted sensi-
tivity 3 months after vector delivery compared to baseline in two 
out of three subjects, whereas no significant changes were reported 
in central visual acuity.12,13
We reported, at short-term follow-up, amelioration in retinal 
and visual function in all three subjects treated with a low dose 
(1.5 × 1010 particles/eye) of AAV2-hRPE65v2.14 Improvement in 
objective measures including PLR and reduction in nystagmus 
were accompanied by increased central visual acuity in three out 
of three subjects and ability to navigate an obstacle course in one 
out of three subjects.14 The significant improvement in retinal and 
visual function we observed as early as 1 month after treatment14 
and through 1.5 years after treatment allows us to: (i) quantitatively 
assess whether visual function improves, deteriorates, or remains 
stable over time after gene transfer, and (ii) compare the influence 
of the treatment with the untreated condition: i.e., evaluate the 
possibility that natural history of this disease has been altered.7 We 
have extended the follow-up in our cohort of subjects treated with 
the low-vector dose through 1.5 years after vector administra-
tion. Here, we show the safety and tolerability of the gene therapy 
approach as well as the stability of its therapeutic efficacy.
results
safety profile
In the follow-up visits through 1.5 years after surgery, immuno-
logic  responses  were  benign  and  no  serious  adverse  events 
occurred.  Serum  antibodies  to  the  RPE65  transgene  product 
were not detected after vector administration. There was a mild 
increase in serum neutralizing antibodies to AAV2 at day 90 in 
subject 1 and at day 14 in subject 2 (Supplementary Table S1). 
Levels diminished thereafter and had returned to baseline levels 
by day 365 after vector administration.
In subjects 1 and 3, fundus photography and optical coher-
ence tomography performed on the treated eye at 1.5 years after 
surgery show an unchanged macular profile and thickness com-
pared to baseline. In subject 2, a stage 4 macular hole developed 
14 days after surgery. There was no expansion of this hole over the 
1.5-year follow-up period (Figure 1). The macular hole did not 
prevent the vision improvement observed as early as 30 days after 
injection. Visual acuity (VA) in all three subjects was stable for up 
to 1.5 years, the last time point of observation.
efficacy profile
All three subjects reported that the improvement in vision percep-
tion in dimly lit environments they noticed starting 2 weeks after 
therapy was maintained through 1.5 years, the latest time point for 
the analysis reported here.
objective evaluation of visual function
Analysis of the PLR. In normal-sighted individuals, a stimulus 
  delivered to either eye alone will cause both pupils to constrict 
equally—i.e.,  the  PLR  response  is  consensual  (Figure  2,  con-
trols). When the light is removed, both pupils normally expand. 
Successive illumination of right and left eyes thus leads to oscil-
lations in pupil diameters of both eyes (Figure 2, controls). PLRs 
are significantly impaired in subjects with LCA. We showed pre-
viously that subretinal delivery of AAV2.hRPE65v2 resulted in 
improvement in PLRs only for stimuli in the injected eye. This 
results in the appearance of a relative afferent pupillary defect of 
the untreated eye; i.e., the injected eye has better retinal function/
PLR sensitivity than the untreated eye.14 The differences can be 
quantitated through measures of the velocity and the amplitude 
of the PLR (VPLR and amplitude of pupillary constriction APC, 
respectively).
Measurement of PLR in the study subjects provided an objec-
tive evaluation of the transmission of impulses initiated in photo-
receptors through the retinal ganglion cells toward pupillomotor 
centers in the central nervous system. Baseline testing of PLR 
showed no detectable difference in VPLR and APC between the 
two eyes in all three subjects. The PLR of the three subjects were 
much less sensitive to light than those of control subjects.14 As 
soon as 1 month after injection, when eyes were exposed to alter-
nating brief (0.2 seconds) flashes of light (test 1), both VPLR and 
APC increased in the injected eye relative to that of the uninjected 
eye. The differences between the PLRs and APCs in the injected 
and the uninjected eyes persisted through 1.5 years (day 545) for 
all subjects, the latest timepoint tested (Figure 2). Representative 
PLRs in Figure 2 show presence of a PLR in the injected right eyes 
(asterisks). The responses in the uninjected left eyes are unchanged 
from baseline—i.e., responses are flat or are significantly reduced 
compared to the injected right eyes.14 The asymmetries are similar 
to those observed at the previous timepoints: day 446 for subject 1 
(VPLR: P < 0.0001; APC: P = 0.001) (Figure 2a), day 365 for sub-
ject 2 (VPLR: P = 0.03; APC: P = 0.007) (Figure 2b) and day 305 
for subject 3 (VPLR: P = 0.004; APC: P = 0.001) (Figure 2c; see 
also Supplementary Appendix). Whereas most of the improve-
ment occurred in the first 1–4 months after injection in all three 
subjects, there was evidence of further improvement in velocity 
between day 150 and 415 timepoints (and then with this improve-
ment persisting through day 545) in subject 1 (P = 0.007; also see 
changes in downward slopes over time after stimulation of the 
right eye in Figure 2a).
Additional  testing  was  performed  by  exposing  the  eyes  to 
alternating longer duration (1.0 second) flashes (test 2). Similar to 
the results using the short flashes, both the velocity and the con-
striction amplitudes of the pupillary light response were increased 
Baseline
Subject 1
Subject 2
Subject 3
Day 30 1.5 year
Figure 1  Fundus photographs and corresponding optical coherence 
tomography images through the fovea are shown for all three sub-
jects at baseline, day 30, and 1.5 years after gene delivery. In subject 
2, the epiretinal membrane is visible at baseline (arrow). A full-thickness 
macular hole is apparent on day 30 and 1.5 years. The adjacent retina 
remains attached.Molecular Therapy  vol. 18 no. 3 mar. 2010  645
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in the injected eyes relative to the uninjected eyes at ~1–1.5 years 
after injection. The P values comparing the velocities at day 415, 
day 365, and day 305 after injection of subject 1, subject 2, and 
subject 3, are P = 0.01, 0.09, and 0.001, respectively. The P values 
comparing the constriction amplitudes at those same long-term 
timepoints are P = 0.04, 0.32, and 0.02, respectively for subject 
1, subject 2, and subject 3; also note the changes in constric-
tion amplitudes over time after stimulation of the right eye in 
Figure 2a–c (also see Supplementary Appendix). Overall these 
results suggest that the improvement in PLR observed in subjects 
1–3 is stable for at least 1 year after vector administration.
Ocular motility testing. Digital eye-movement videos showed at 
baseline that subject 1 had exotropia (outward deviation of the 
visual axis in one or both eyes) and multiplanar, vertical-greater-
than  horizontal,  moderate-amplitude  and  moderate-frequency 
ocular  movements;  subject  2  had  largely  oblique,  jerk,  low-
  amplitude, and moderate-frequency ocular movements; subject 
3 had exotropia of the right eye and a largely vertical, pendular, 
low-amplitude, low-frequency oscillation. After treatment in all 
three subjects the eye movements were constant, and symmetric, 
with frequency oscillation that increased in intensity in eccen-
tric gaze and with monocular cover. At follow-up from day 60 
on, subjects 1 and 3 had at least a 50% decrease in both mon-
ocular and binocular nystagmus frequency in primary position 
(Table 1).  All subjects also show a significant reduction in binoc-
ular nystagmus amplitude in primary gaze at follow-up (Table 2). 
Interestingly, we also noticed a decrease in exotropia in subjects 
1 and 3, as evident from the decreased interpupillary distance 
(Figure 3; Table 3). In patient 3, we also observed a change from 
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Figure 2  representative long-term follow-up pupillometry results in the three subjects. The pupillary light reflexes after dark adaptation are 
shown as a response to alternating stimulation of the right eye and the left eye. The curves represent the diameter of the pupils; the right pupil is 
slightly higher than the left pupil in each trace where two pupils are shown. The following pupil traces were displaced vertically to facilitate compari-
sons: subject 1 day 545, subject 2 baseline, day 365, day 545; subject 3 baseline, subject 3 day 365, subject 3 day 545. The average pupil diameters 
immediately prior to the first light exposure in the series were as follows: subject 1, 6.4 mm for both pupils at day 175; 5.6 (right), 5.28 (left) at day 
446, and 4.9 (right) at day 545; subject 2: 7.1 for both pupils at baseline, 7.8 mm (right) and 7.1 mm (left) pupil at day 60; 4.7 mm for both pupils at 
day 365 and 4.96 mm (left) pupil at day 545; subject 3: 6.6 mm for both pupils at baseline; 6.3 (right) and 6.1 (left) at day 30; 5.8 (right), 5.4 at day 
305 and 4.56 mm at day 545. Alternating stimulation with light of 10.0 lux, 10.0 lux, and 0.04 lux, respectively for subjects 1, 2, and 3. Timepoints 
(days) with respect to injection are indicated to the right of the traces. Results for test 1 [exposure of eyes to alternating brief (0.2 seconds) flashes 
of light] are shown for subjects 1 and 2; results for test 2 [exposure of eyes to alternating long (1.0 seconds) flashes of light] are shown for subject 3. 
Alternating stimuli were presented 2 seconds after the recording was initiated.646  www.moleculartherapy.org  vol. 18 no. 3 mar. 2010     
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exotropia in the right eye to alternating exotropia with a slight 
  predominance of the right eye. These results show that following 
RPE65 gene delivery to one eye of the LCA2 subjects there is a 
stable reduction in ocular movements of both eyes accompanied 
by an improved ocular motility.
Electroretinographic  testing.  Full-field  electroretinography 
(ERG) performed before and after surgery and up to 1.5 years in 
all three subjects shows no change in retinal responses to flash.
subjective evaluation of visual function
Acuity testing. Visual acuity had significantly improved in the in-
jected eye in all three subjects as early as 1 month after injection as 
previously reported.14 Here, at the 1.5-year timepoint, visual acuity 
has continued to improve compared to previously reported values 
assessed short-term after treatment.14 LogMAR (Logarithm of the 
Minimum Angle of Resolution) score improved by 0.21 for sub-
ject 1 (from 3 to 5 lines on the eye chart at 50 cm), by 0.19 for sub-
ject 2 (from 4.5 to 6.2 lines on the eye chart at 50 cm) and by 0.24 
for subject 3 (from 8 to 10.4 lines of letters at 50 cm) (Table 4).
The  VA  data  (Figure  4)  show  that  the  greatest  gain  in  the 
injected eye was obtained in the first few months following injection. 
However, interestingly, there was an additional improvement there-
after, although the low number of timepoints, and thus tests, allows 
us to present descriptive statistical data only. It is worth emphasiz-
ing that in both subjects 1 and 3, the treated eyes, the worst eyes 
before injection, improved and have become the eyes with the bet-
ter VA. Furthermore, improved, albeit not statistically significant, 
VA was evident in subject 2’s uninjected eye as early as the first few 
days after gene delivery (going from an average LogMAR of 1.40 
at baseline to an average LogMAR of 1.14 in the first 2 weeks after 
injection (P = 0.34) and this improvement has continued up to 1.5 
years after injection. In subjects 1 and 3 there was no statistically 
significant improvement in the untreated eyes between baseline and 
short-term follow-up14 whereas a slight improvement was observed 
in subject 1 between short term (day 150) and 1.5-year follow-up 
(Figure 4). In subject 3 no improvement was observed between 
short term (day 45) and 1.5-year follow-up (Figure 4).
Subject 12 3
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Nystagmus
amplitude
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Motion
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Pre
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Figure 3  Pre- and postinjection nystagmus analysis. (a,b) Frames from pre- and postinjection video recordings in subject 1 with motion paths 
of the pupils superimposed. Motion of each eye is shown by indicating the location of the center of the pupil over 100 sequential frames (total of 4 
seconds) isolated from the video recordings. In b, the motion path is isolated. In c, pre- and postinjection measurements in subject 1 show reduction 
in interpupillary distance with concomitant changes in the corneal light reflexes (arrowheads). Similar analyses are shown for (d–f) subject 2 and 
(g–i). Analyses show a significant decrease in binocular amplitude of nystagmus in primary position in subjects 2 and 3 after injection and a smaller 
decrease in amplitude in subject 1 after injection. There is also a reduction in interpupillary distance in (i) subject 3.
table 1  nystagmus frequency measured in primary gaze as a function 
of time after injection
subject
right eye left eye
Before After Before After
Baseline day 30 1.5 year Baseline day 30 1.5 year
1 2.0 1.2 1 2.0 1.2 1
2 1.0 0.9 0.8 1.0 0.9 0.8
3 1.5 1.4 0.7 1.37 1.1 0.6
table 2  Amplitude of nystagmus measured in primary gaze before 
and after injection (degrees)
subject
right eye left eye
Before After Before After
Baseline day 60 1.5 year Baseline day 30 1.5 year
1 5.1 4.9* 2.6**** 5.0 4.8 2.3****
2 8.5 4.0*** 1.5***** 8.0 5.1**** 1.7*****
3 9.1 3.4** 1.6** 4.9 3.6**** 1.0
Comparison with baseline: *P = 0.01; **P < 0.003; ***P = 0.001; ****P < 0.0005; 
*****P < 0.0001.
table 3  Maximum interpupillary distance (mm) measured in primary 
gaze
subject
Before After
Baseline day 60 1.5 year
1 61.76 + 0.1 60.6 + 0.1*** 60.1 + 0.1***
2 61.29 + 0.3 62.2 + 0.3*** 63.94 + 0.5***
3 57.8 + 1.1 55 + 0.2** 55.38 + 0.2*
Comparison with baseline: *P = 0.01; **P = 0.004, ***P < 0.0001.Molecular Therapy  vol. 18 no. 3 mar. 2010  647
© The American Society of Gene & Cell Therapy
Long-term Safety and Efficacy of LCA Gene Therapy
Goldmann visual field tests. Goldmann visual field tests carried 
out 1.5 years after injection did not show a significant change in 
the total measured area seen by the injected eye (or the uninjected 
eye) compared to early postinjection changes which were signifi-
cant compared to baseline (data not shown). The small, enlarge-
ment of the peripheral isopters observed in subject 2 may reflect 
the extreme variability of perimetric measurements in low-vision 
subjects.15
Mobility testing. In the ability to navigate an obstacle course, all 
three subjects, compared to day 30,14 showed a slight continuous 
improvement up to 1.5 years after surgery in terms of both time 
necessary to complete the test and number of obstacles avoided 
(see Table 5 and subject 2; Supplementary Video S1). A learn-
ing effect in this subjective test cannot be excluded, although the 
course configuration was changed for each test.14 Subject 2 ap-
pearing in the Supplementary Video S1 signed media consents.
dIscussIon
In LCA, vision deteriorates over time bilaterally and patients 
usually reach total blindness by the third or fourth decade of 
life. Our results show that improvement in both subjective and 
objective measurements of visual/retinal function observed as 
early as 1 month after subretinal administration of a low dose of 
AAV2-hRPE65v2 in three subjects persists through the 1.5-year 
postinjection timepoint.14 The improvement in both velocity and 
amplitude of PLR is particularly relevant considering the objec-
tivity of this test which is used to probe transmission of retinal 
signals to higher nervous centers.3 This test also revealed a sus-
tained improvement in light sensitivity in each of the subjects. 
In addition, a significant reduction in nystagmus was observed 
in all subjects continuing through 1.5 years after injection. Even 
though the subjects received uniocular treatment, the nystag-
mus showed binocular damping. There is evidence that both 
animals16 and humans17,18 with nystagmus due to  vitreous  opacity 
or   cataract, show improvement of ocular motility in both eyes 
when receiving uniocular treatment that restores visual function. 
This could be due to a net improved visual acuity that allows 
a more stable fixation and hence better ocular-motor response 
in both eyes. Alternatively, it may also reflect the combining of 
the visual signals from each eye in the lateral geniculate nucleus 
as suggested by Jacobs et al.16 Alternatively, it may result from 
increased visual input which initiates and maintains the calibra-
tion of the ocular motor system.17,18 Indeed, results from canine 
and humans studies suggest that late plasticity enables the self-
recalibration of the ocular motor system once sufficient visual 
input is available.16
We have additionally observed persistence over time of a 
significant improvement in VA in the injected eyes. Notably, in 
subjects 1 and 3, the injected eye, the worst eye before treatment, 
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Figure 4  Visual acuity (logMAr on the left y axis and snellen value on the right y axis) over time after gene delivery. Baseline is indicated as 
day 0; gene delivery (no visual acuity measurement) is on day 1.
table 5  Performance of the patients in the mobility test
obstacles avoided time spent in maze
Subject 1
  Baseline Unable to perform Unable to perform
  Day 180 12/14 55 seconds
  1.5 years 12/14 1 minute 4 seconds
Subject 2
  Baseline Unable to perform Unable to perform
  Day 180 13/14 37 seconds
  1.5 years 14/14 57 seconds
Subject 3
  Baseline Unable to perform Unable to perform
  Day 180 12/14 50 seconds
  1.5 years 13/14 30 seconds
table 4  etdrs visual acuity results in injected eye (right) and uninjected eye (left)
subject 1 subject 2 subject 3
right left right left right left
Before HM (2) 20/1,040 (1,72) HM (2) 20/500 (1,4) 20/640 (1,5) 20/220 (1,05)
Postinjectiona 20/1,050 (1,72) 20/1,100 (1,74) 20/710 (1,55) 20/220 (1,04) 20/290 (1,16) 20/210 (1,03)
1.5 years 20/640 (1,51) 20/762 (1,58) 20/459 (1,36) 20/126 (0,80) 20/167 (0,92) 20/182 (0,96)
Abbreviations: ETDRS, Early Treatment Diabetic Retinopathy Study; LogMAR, Log of the Minimum Angle of Resolution.
LogMAR score value are indicated in parenthesis.
aPublished data: day 150 for subject 1; day 80 for subject 2; day 45 for subject 3.648  www.moleculartherapy.org  vol. 18 no. 3 mar. 2010     
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improved. Even though a placebo effect cannot be excluded 
because the subjects were aware of which eye was injected, the 
differences in the number of letters read at baseline versus after 
injection  timepoints  are  significant  using  conservative  ana-
lytic criteria. Together, the improvement in VA, the reduction 
in nystagmus and strabismus, and the PLR improvement sug-
gest that significant amelioration of visual function occurs after 
treatment. No change was observed compared to baseline in the 
full-field ERG but the test was likely not informative due to: the 
limited area of retina treated; the low-vector dose injected; the 
minimal amount of photoreceptors remaining at this advanced 
stage  of  disease;  the  capability  of  retinal  pigment  epithelial 
(RPE) cells to synthesize 11-cis-retinal despite restoration of 
RPE65 expression; and the capability of photoreceptors to use 
11-cis-retinal.
In contrast to this study, Bainbridge et al.11 and Cideciyan 
et  al.12  did  not  report  improved  acuity  in  their  study  subjects 
despite evidence for improved retinal function especially for rod 
photoreceptors. Several factors could account for this difference. 
First, the subjects in their studies had substantially better acuity 
at baseline than those described here and it is unlikely that they 
would manifest improvement even with restoration of rod function 
in the paramacular area where resolution is limited. In addition, 
in the present study, the subretinal injection was delivered close to 
the central macula where both rod and cone density and, thereby, 
resolution is greater. It is possible that some of the improvement 
in VA measured in our study results from neuroanatomical and 
physiologic changes in the brain secondary to enhanced stimu-
lation from the AAV-transduced retinal neurons. This possibil-
ity will be explored in future studies. Nonetheless, improvements 
in the PLR correlated in time with improvements in VA in the 
current study, providing objective confirmation of the subjective 
measures of efficacy. Interestingly, we observed improvement in 
VA of the untreated eye in subject 2 that was not associated with 
an improvement in the PLR. This result may be due to the reduc-
tion in nystagmus amplitude of both eyes, resulting in more stable 
fixation.
An analysis of the mobility tests performed at various time-
points after injection shows a gradual and more confident behav-
ior of the subjects when navigating the obstacle course. A better 
perception of the course and its obstacles was evident.
Finally, the long-lasting improvements in retinal/visual func-
tion in the three subjects were achieved safely and with minimal 
immune response and no serious adverse events. Although low 
levels  of  neutralizing  antibodies  to  AAV2  did  develop  in  two 
of the three subjects, those responses were transient and levels 
returned to baseline between 3 and 12 months after administra-
tion. Interestingly, neutralizing antibody levels plateaued at differ-
ent timepoints following surgery for the two responding subjects. 
The significance of the differences in timecourses is unknown. The 
macular hole that developed in one patient 14 days after injection 
did not show signs of evolution at long term. In accordance with 
our previous hypothesis,11 the macular hole can be considered a 
result of the constriction of a pre-existing membrane stimulated 
by the surgical procedure.
In all three trials testing the safety and efficacy of AAV2 in 
the retina of LCA2 subjects, no serious adverse events have been 
reported.11,13,14  In  recent  reports  from  Bainbridge  et  al.11  and 
Cideciyan et al.12,19 subjects were followed-up to 1 year. Neither 
group showed significant improvements in objective test results, 
although Cideciyan et al. used subjective testing (dark adaptom-
etry) to show persistence of enhanced light sensitivity.12,19 Use of 
the PLR response allows an objective comparison between retinal 
function in treated and control eyes that provides a robust basis 
to determine any rescue effect of the intervention. Cideciyan et al. 
also used subjective testing to show improved fixation in one of 
three subjects.20 Here, we show improved fixation in three out of 
three subjects, evident much sooner than 1–1.5 years, using objec-
tive criteria.
The data from the 1.5-year follow-up in the LCA2 subjects 
treated in this trial allow us to draw some important conclusions: 
(i) transgene expression resulting from AAV delivery is stable 
over time, thus ruling out the possibility that the improvement in 
visual function observed is the result of a transient neurotrophic 
effect induced by the surgical procedure; (ii) the kinetics of the 
improvement with early amelioration which stabilizes over time 
are  consistent  with  AAV2-hRPE65v2-mediated  correction  of  a 
visual  cycle  enzymatic  defect:  indeed  AAV2-mediated  RPE65 
gene expression occurring in animal models a few weeks after 
gene  transfer  is  expected  to  rapidly  “unlock”  the  visual  cycle 
blocked by RPE65 deficiency; (iii) although longer term follow-up 
is required, efficacy of gene transfer seems not to be affected by 
the  progressive  degenerative  nature  of  LCA2;  and  (iv)  AAV2-
mediated gene transfer to the human retina, similarly to what was 
observed in muscle21 and central nervous system,22 does not elicit 
the cytotoxic T-lymphocyte responses to AAV capsids observed in 
human liver.23 The safety and efficacy results reported here suggest 
that the retina is an amenable target for stable AAV2-mediated 
gene transfer in humans.
MAterIAls And Methods
All details of the design, consent, and vector administration in this phase 
1 clinical trial have previously been reported.14 Briefly, three LCA subjects, 
(referred to here as subjects 1, 2, and 3) aged 19–26 years old were first 
evaluated at the Second University of Napoli (Napoli, Italy) and received 
their diagnosis based on visual and retinal function studies.4 They then 
underwent mutation screening for LCA genes and were assigned a molecular 
diagnosis of LCA2 at the Telethon Institute of Genetics and Medicine. After 
informed consent and confirmation of trial eligibility criteria, including 
legal blindness based on visual acuity and visual field testing as well as 
independent evaluation of the likelihood that the mutations were disease-
causing (Carver Lab, Iowa City, IA), the eye with worse visual function was 
selected for delivery of AAV2-hRPE65v2. The vector was manufactured 
by the Center for Cellular and Molecular Therapeutics at The Children’s 
Hospital of Philadelphia (Philadelphia, PA) and delivered subretinally at 
The Children’s Hospital of Philadelphia as described.14
Subjects were evaluated before and after surgery at designated follow-
up visits (1, 2, 3, 14, 30, 60, 90, 180, 270, 365 days, and 1.5 years) by complete 
ophthalmic  examination,  a  general  physical  examination,  and  clinical 
and laboratory tests, including an assessment of vector biodistribution 
(shedding) and immune response. Baseline tests and follow-up visits up 
to day 30 were performed at both The Children’s Hospital of Philadelphia 
and Second University of Napoli while the follow-up visits from day 60 to 
1.5 years were performed at Second University of Napoli.
Efficacy for each subject was monitored with objective and subjective 
measures  of  vision,  as  described  previously.14  Objective  measures 
included evaluation of the PLR, ERG, and nystagmus testing. Bilateral Molecular Therapy  vol. 18 no. 3 mar. 2010  649
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full-field ERGs were recorded using LACE Elettronica Electrophysiology 
system  (Pisa,  Italy),  with  ERG-jet  contact  lens  electrodes  following 
International Society for Clinical Electrophysiology of Vision  standard 
guideline.24
Pupil responses were recorded simultaneously in both eyes with a 
Procyon P2000 pupillometer and PupilFit4 software (Monmouthshire, 
UK) (N.J. Volpe, L. Dadvand, S.K. Kim, M.G. Maguire, G.-S. Ying, M.L. 
Moster et al., manuscript submitted). Pupillary responses to light were 
recorded with variants of the basic protocol. Test 1 presented the light 
stimulus for 0.2 seconds followed by a 1 second dark interval. Test 2 
used a longer stimulus cycle with light stimulus presented for 1 second 
followed by a 0.6 seconds dark interval.25 Nystagmus was characterized 
qualitatively and quantitatively by analysis of motion paths in videos 
taken at baseline and postinjection timepoints. Interpupillary distances 
were measured directly from video frames.
Subjective  measures  included  standard  tests  of  VA,  kinetic  visual 
field measured using Goldmann perimetry (Haag Streit Perimeter 940; 
Haag Streit, Mason, OH),26 and mobility testing to assess the ability of 
the subjects to navigate an obstacle course. For mobility testing different 
mazes  were  used  each  time  the  test  was  performed  and  number  of 
obstacles avoided or hit, number of landmarks identified and time spent 
in the maze were assessed.
Statistical analyses. As described in Maguire et al.,14 VA was measured with 
Early Treatment Diabetic Retinopathy Study (ETDRS) charts at 0.5 m and 
at 2.0 m and letter counts were recorded. These were then converted into 
the correct LogMAR score. For statistical purposes, the VA scores at base-
line, day 30, and later were calculated using the average of at least four 
measurements at each time point. Comparisons were made between the 
VA results recorded in follow-up with the baseline and early postinjection 
measurements. Pupillometry data were quantified through comparison of 
VPLRs and APCs obtained in a series of recordings obtained using dif-
ferent intensities of light stimuli (0.04, 0.4, and 10 lux). Recordings were 
also obtained after stimulating the right eye first or the left eye first. With 
the exception of subject 1, in whom only one set of baseline recordings 
was obtained, baseline and postinjection recordings were obtained on at 
least two different days after 40 minutes of dark adaptation. Significance of 
changes in amplitudes and velocities of pupil constriction in the pupillom-
etry studies were evaluated using two different methods. The paired t-test 
was used to determine whether there were   differences in response result-
ing from light stimulation of the injected (right) eyes and the control (left) 
eyes. Analysis of variance and post hoc pairwise comparisons were used 
to determine whether there were differences in response at baseline and 
follow-up timepoints. Significance of changes in interpupillary distances 
an nystagmus amplitudes were evaluated with the paired t-test.
suPPleMentArY MAterIAl
Table S1.  Serum neutralizing antibodies directed against AAV2.
Appendix. Summary of data analyzed for statistics of pupillo  metry 
responses in subjects 1, 2, 3 (pupillometry response summary). 
Video S1. Subject 2 navigates the obstacle course with few errors at 
1.5 years after injection.
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